Compare PSQH & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSQH | ALGS |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 34.6M |
| IPO Year | 2021 | 2020 |
| Metric | PSQH | ALGS |
|---|---|---|
| Price | $6.34 | $7.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 534.5K | 127.4K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.00 | ★ 88.30 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,685,987.00 | $2,186,000.00 |
| Revenue This Year | $80.20 | $32.20 |
| Revenue Next Year | $34.74 | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1096.61 | N/A |
| 52 Week Low | $0.36 | $3.98 |
| 52 Week High | $6.94 | $13.69 |
| Indicator | PSQH | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 74.78 | 63.90 |
| Support Level | $0.61 | $6.25 |
| Resistance Level | N/A | $7.97 |
| Average True Range (ATR) | 0.64 | 0.63 |
| MACD | 0.19 | 0.10 |
| Stochastic Oscillator | 94.85 | 82.49 |
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.